Table 2.

Results of the primary and secondary outcome analyses with one-year follow-up.

	Number of events among SGLT2 inhibitor treated	Number of events among non-SGLT2 inhibitor treated	KM-rate among SGLT2 inhibitor treated	KM-rate among non SGLT2 inhibitor treated	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Composite of first hospitalisation for heart failure or all-cause death	180	1299	8.2	15.8	0.52 (0.45–0.61)	0.70 (0.59–0.82)
First hospitalisation for heart failure	106	600	5.0	7.6	0.66 (0.54–0.82)	0.78 (0.63–0.98)
All-cause death	83	772	4.0	9.5	0.43 (0.35–0.54)	0.64 (0.50–0.80)
Stroke	25	144	1.3	1.9	1.12 (0.63–1.97)	0.86 (0.54–1.35)

Adjusted for age, sex, eGFR, BMI, HbA1c-level, smoking status, clinical frailty score, Killip class at admission, MI classification (STEMI/NSTEMI), left ventricular ejection fraction, year of admission, treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers, statins, aspirin and insulin, diagnosis of hypertension and COPD, and prior stroke, heart failure, and myocardial infarction.

CI, Confidence interval; HR, Hazard ratio; KM, Kaplan–Meier.